Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation [...]
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, announced today the dosing of the first subject in the ...
The Manila Times8h
Jakks Pacific Announces 2025 Annual Meeting Date and Restructuring of Board of Directors
JAKKS Pacific, Inc. (NASDAQ: JAKK) today announced that the Board of Directors (the "Board”) approved the scheduling of the ...
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and BioMarin Pharmaceutical (BMRN)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Perspective Therapeutics (CATX – Research ...
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors
The stock's fall snapped a two-day winning streak.
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day
Shares of Corbus Pharmaceuticals Holdings Inc. CRBP rose 2.35% to $6.10 Tuesday, on what proved to be an all-around positive ...